Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Fernández A, et al. Among authors: reboredo m. BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3. BMC Cancer. 2018. PMID: 30497432 Free PMC article.
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-Galán J, Ales I, Sastre J, Perea S, Hidalgo M. Macarulla T, et al. Among authors: reboredo m. J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4. J Clin Oncol. 2019. PMID: 30523758 Clinical Trial.
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. López R, et al. Among authors: reboredo m. Br J Cancer. 2010 Nov 9;103(10):1536-41. doi: 10.1038/sj.bjc.6605938. Epub 2010 Oct 12. Br J Cancer. 2010. PMID: 20940719 Free PMC article.
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. Carrato A, et al. Among authors: reboredo m. BMC Cancer. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7. BMC Cancer. 2019. PMID: 31159765 Free PMC article. Clinical Trial.
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Rivera F, et al. Among authors: reboredo m. Cancer Chemother Pharmacol. 2019 Jun;83(6):1175-1181. doi: 10.1007/s00280-019-03820-7. Epub 2019 Mar 29. Cancer Chemother Pharmacol. 2019. PMID: 30927036 Free PMC article. Clinical Trial.
First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial.
Quintero Aldana G, Salgado M, Candamio S, Méndez JC, Jorge M, Reboredo M, Vázquez Tuñas L, Romero C, Covela M, Fernández Montes A, Carmona M, Vidal Insua Y, López R; Galician Oncological Research Group (GGIO). Quintero Aldana G, et al. Among authors: reboredo m. Clin Transl Oncol. 2020 Apr;22(4):495-502. doi: 10.1007/s12094-019-02151-6. Epub 2019 Jul 6. Clin Transl Oncol. 2020. PMID: 31280434 Clinical Trial.
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis.
García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, Manzano Mozo JL, Muñoz A, Durán G, Sastre J, Safont MJ, Ferreiro R, Rivera F, González E, Valladares-Ayerbes M, Grávalos C, Alonso-Orduña V, Viéitez JM, Yubero A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). García-Alfonso P, et al. Drugs Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. Epub 2021 Feb 22. Drugs Aging. 2021. PMID: 33615402 Free PMC article.
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Rivera F, et al. Among authors: reboredo m. Cancer Chemother Pharmacol. 2019 Dec;84(6):1365. doi: 10.1007/s00280-019-03964-6. Cancer Chemother Pharmacol. 2019. PMID: 31587095 Free PMC article.
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Rivera F, Massutí B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de Paredes ML, Manzano JL, Galán M, Alsina M, Yuste Izquierdo AL, López C, Díaz-Rubio E, Conde V, Reboredo M, Cano MT, Pachón V, Aranda E. Rivera F, et al. Among authors: reboredo m. Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10. Cancer Chemother Pharmacol. 2015. PMID: 25491381 Clinical Trial.
92 results